UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000048568
Receipt number R000055337
Scientific Title DAPA-BODY Trial
Date of disclosure of the study information 2022/08/04
Last modified on 2022/08/03 16:49:54

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

DAPA-BODY Trial

Acronym

DAPA-BODY Trial

Scientific Title

DAPA-BODY Trial

Scientific Title:Acronym

DAPA-BODY Trial

Region

Japan


Condition

Condition

chronic kidney disease

Classification by specialty

Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the long-term effect of SGLT2 inhibitor dapagliflozin on body composition in chronic kidney disease patients

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

body composition (body fluid volume, fat mass, bone mineral content, and skeletal muscle mass) for 6 and 12 months after the administration of dapagliflozin

Key secondary outcomes

changes in hemodynamic parameters and eGFR for 6 and 12 months after the administration of dapagliflozin


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

SGLT2 inhibitor dapagliflozin 10 mg/day for 12 months

Interventions/Control_2

Treatment without SGLT2 inhibitor dapagliflozin for 12 months

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

90 years-old >

Gender

Male and Female

Key inclusion criteria

CKD patients with or without diabetes
-15 < eGFR < 59 mL/min/1.73 m2 with or without proteinuria
-60 < eGFR mL/min/1.73 m2 with proteinuria

Key exclusion criteria

1. History of renal replacement
2. Current dialysis
3. Type 1 diabetic mellitus
4. Active malignancy

Target sample size

100


Research contact person

Name of lead principal investigator

1st name TAKAHIRO
Middle name
Last name MASUDA

Organization

Jichi Medical University

Division name

Division of Nephrology, Department of Internal Medicine

Zip code

3290498

Address

3311-1 Yakushiji, Shimotsuke, Tochigi

TEL

0285587346

Email

takamasu35@gmail.com


Public contact

Name of contact person

1st name TAKAHIRO
Middle name
Last name MASUDA

Organization

Jichi Medical University

Division name

Division of Nephrology, Department of Internal Medicine

Zip code

3290498

Address

3311-1 Yakushiji, Shimotsuke, Tochigi

TEL

0285587346

Homepage URL


Email

takamasu35@gmail.com


Sponsor or person

Institute

JichiMedical University

Institute

Department

Personal name



Funding Source

Organization

The Kidney Foundation

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

Shin-Oyama City Hospital, Nasu Minami Hospital

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Shin-Oyama Hospital

Address

2251-1 Hitotonoya, Oyama, Tochigi

Tel

0285-36-0200

Email

takamasu35@gmail.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

新小山市民病院、那須南病院


Other administrative information

Date of disclosure of the study information

2022 Year 08 Month 04 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

100

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2020 Year 12 Month 11 Day

Date of IRB

2020 Year 12 Month 25 Day

Anticipated trial start date

2021 Year 01 Month 13 Day

Last follow-up date

2023 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2022 Year 08 Month 03 Day

Last modified on

2022 Year 08 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055337


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name